• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore June 6 Strides Arcolab Ltd has announced that it has received tentative USFDA approvals for two new applications for HIV drugs.

They are fixed dose combinations of Lamivudine/Stavudine 150 mg/40 mg tablets and Lamivudine/Zidovudine 150/300 mg tablets - both co-packaged with Efavirenz 600mg tablets.

Mr Arun Kumar, Vice-Chairman and MD, said, "We now have approvals for all key frontline HIV/AIDS medicine.

"This, combined with our pipeline of second line drugs, will make us a significant player in the quality, affordable multi-source ARVs business segment."

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Great Eastern Energy reports growth in CBM reserves

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line